Neurocrine Biosciences NBIX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $478.6M+40.2% | $341.3M+36.7% | $249.7M+61.6% | $154.5M+59.4% | ||
| $26M+10.6% | $23.5M+32.0% | $17.8M+17.9% | $15.1M+38.5% | ||
| $217.9M+11.5% | $195.5M+0.6% | $194.3M+12.2% | $173.1M+29.0% | ||
| $165.4M+234% | -$123.1M— | —— | $19.1M— | ||
| —— | —— | —— | —— | ||
| —— | $41.8M-55.3% | $93.5M-42.4% | $162.2M+471% | ||
| $160.2M+269% | $43.4M— | —— | $114.6M+102% | ||
| —— | $100K-85.7% | $700K— | —— | ||
| —— | —— | $91.6M— | —— | ||
| $4.1M+13.9% | $3.6M+2.9% | $3.5M+600% | $500K— | ||
| —— | -$37.1M-231% | $28.4M-7.8% | $30.8M+47.4% | ||
| —— | —— | —— | —— | ||
| $782.7M+31.5% | $595.4M+52.7% | $389.9M+14.9% | $339.4M+32.3% | ||
| $36.4M-4.7% | $38.2M+35.0% | $28.3M— | —— | ||
| $1.32B+25.0% | $1.06B-23.5% | $1.38B+122% | $621.2M-22.4% | ||
| —— | —— | —— | —— | ||
| -$264.4M— | —— | -$467.1M— | —— | ||
| —— | $300M— | $0— | $0— | ||
| $129.4M+6.0% | $122.1M+87.0% | $65.3M+46.1% | $44.7M+62.5% | ||
| —— | —— | —— | —— | ||
| —— | -$513.1M-886% | $65.3M— | —— | ||
| $480M+2,752% | -$18.1M— | —— | —— | ||
| $81.4M-62.6% | $217.5M+322% | $51.5M+258% | $14.4M— | ||
| $12.7M-51.5% | $26.2M+43.2% | $18.3M+595% | -$3.7M+50.0% | ||
| $4.1M+13.9% | $3.6M+2.9% | $3.5M+600% | $500K— | ||
| —— | —— | —— | —— | ||
| $26.8M+158% | $10.4M+1,256% | -$900K— | —— | ||
| $1.09B+12.6% | $967.5M-0.5% | $972.4M+90.3% | $511M-26.8% | ||
| —— | —— | $2.5M— | —— | ||
| $748.7M+34.4% | $557.2M+54.1% | $361.6M+12.0% | $322.9M+35.8% | ||
| $748.7M+34.4% | $557.2M+54.1% | $361.6M+12.0% | $322.9M+35.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Neurocrine Biosciences generate?
- Neurocrine Biosciences (NBIX) generated $863.7M in operating cash flow over the trailing twelve months.
- What is Neurocrine Biosciences's free cash flow?
- After $34.8M of capital expenditures, Neurocrine Biosciences's free cash flow was $831.3M over the trailing twelve months, up 68.9% year over year.
- Where does Neurocrine Biosciences's cash flow data come from?
- Every line is extracted from Neurocrine Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
